TiGenix NV (Euronext Brussels and Nasdaq: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Considered to be the most advanced stem cell company in the world, with lead product candidate Cx601 having reported positive phase III results and long-term efficacy. Cx601 is being developed for complex perianal fistulas, which is a complication of Crohn’s Disease. Cx601 has been granted Orphan Drug status in Europe and expects to receive its European marketing authorization by year-end 2017. TiGenix has an exclusive licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda maintains the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com.
Looking for a particular TiGenix employee's phone or email?
TiGenix Questions
The TiGenix annual revenue was $1.1 million in 2026.
Nathalie Borghmans is the Executive Assistant of TiGenix.
20 people are employed at TiGenix.
TiGenix is based in Leuven, Flander.
The NAICS codes for TiGenix are [541, 3254, 54, 325, 32541, 5417, 32].
The SIC codes for TiGenix are [28, 283].
Top TiGenix Employees
-
Nathalie Borghmans
Executive Assistant at TiGenix
Brussels, BE3 -
Isabelle Maes
Executive Assistant at TiGenix
Antwerp, BE1
Related Companies
